|
Disease |
|
|
|
Detail |
| hsa-let-7a |
|
Causal |
let-7 regulates self renewal and tumorigenicity of breast cancer cells. |
2007 |
|
|
|
|
|
|
| hsa-let-7f-1 |
|
Unspecified |
Real-time expression profiling of microRNA precursors in human cancer cell lines. |
2005 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-181b-1 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-29b-2 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-146a |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-let-7f-2 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-let-7i |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-204 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-let-7d |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-let-7a-3 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-136 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-206 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-213 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-170 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-10b |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-122a |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-128b |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-145 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-143 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-202 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-203 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-149 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-101-1 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-125a |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-125b |
|
Causal |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-191 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-196a |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-196a-2 |
|
Unspecified |
MicroRNA gene expression deregulation in human breast cancer. |
2005 |
|
|
|
|
|
|
| hsa-miR-10b |
|
Causal |
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-124a |
|
Causal |
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. |
2007 |
|
|
|
|
|
|
| hsa-miR-663 |
|
Unspecified |
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-9-1 |
|
Unspecified |
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-152 |
|
Unspecified |
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-124a-3 |
|
Unspecified |
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-148a |
|
Unspecified |
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-125a |
|
Causal |
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. |
2006 |
|
|
|
|
|
|
| hsa-miR-125b |
|
Causal |
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. |
2006 |
|
|
|
|
|
|
| hsa-miR-206 |
|
Causal |
Endogenous human microRNAs that suppress breast cancer metastasis. |
2008 |
|
|
|
|
|
|
| hsa-miR-335 |
|
Causal |
Endogenous human microRNAs that suppress breast cancer metastasis. |
2008 |
|
|
|
|
|
|
| hsa-miR-126 |
|
Causal |
Endogenous human microRNAs that suppress breast cancer metastasis. |
2008 |
|
|
|
|
|
|
| hsa-miR-127 |
|
Causal |
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. |
2006 |
|
|
|
|
|
|
| hsa-miR-205 |
|
Unspecified |
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-145 |
|
Unspecified |
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-146a |
|
Causal |
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. |
2006 |
|
|
|
|
|
|
| hsa-miR-206 |
|
Causal |
The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. |
2007 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
miR-21-mediated tumor growth. |
2007 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. |
2008 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. |
2007 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). |
2007 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-27a |
|
Causal |
The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. |
2007 |
|
|
|
|
|
|
| hsa-miR-520c |
|
Causal |
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. |
2008 |
|
|
|
|
|
|
| hsa-miR-373 |
|
Causal |
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. |
2008 |
|
|
|
|
|
|
| hsa-miR-205 |
|
Causal |
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. |
2008 |
|
|
|
|
|
|
| hsa-miR-429 |
|
Causal |
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. |
2008 |
|
|
|
|
|
|
| hsa-miR-141 |
|
Causal |
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. |
2008 |
|
|
|
|
|
|
| hsa-miR-200a |
|
Causal |
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. |
2008 |
|
|
|
|
|
|
| hsa-miR-200b |
|
Causal |
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. |
2008 |
|
|
|
|
|
|
| hsa-miR-200c |
|
Causal |
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. |
2008 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. |
2008 |
|
|
|
|
|
|
| hsa-miR-663 |
|
Unspecified |
Epigenetic inactivation of microRNA genes in mammary carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-9-1 |
|
Unspecified |
Epigenetic inactivation of microRNA genes in mammary carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-152 |
|
Unspecified |
Epigenetic inactivation of microRNA genes in mammary carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-124a-3 |
|
Unspecified |
Epigenetic inactivation of microRNA genes in mammary carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-148a |
|
Unspecified |
Epigenetic inactivation of microRNA genes in mammary carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-196a-2 |
|
Unspecified |
microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. |
2009 |
|
|
|
|
|
|
| hsa-miR-96 |
|
Causal |
Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-182 |
|
Causal |
Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-27a |
|
Causal |
Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-661 |
|
Causal |
MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. |
2009 |
|
|
|
|
|
|
| hsa-miR-18a |
|
Unspecified |
Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-195 |
|
Unspecified |
Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-200c |
|
Causal |
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-193b |
|
Causal |
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast
cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-181a |
|
Unspecified |
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth |
2009 |
|
|
|
|
|
|
| hsa-miR-26a |
|
Unspecified |
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth |
2009 |
|
|
|
|
|
|
| hsa-miR-200b |
|
Causal |
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-200c |
|
Causal |
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-31a |
|
Causal |
Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis |
2009 |
|
|
|
|
|
|
| hsa-miR-125a |
|
Causal |
MicroRNA-125a represses cell growth by targeting HuR in breast cancer |
2009 |
|
|
|
|
|
|
| hsa-miR-146a |
|
Causal |
Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. |
2008 |
|
|
|
|
|
|
| hsa-miR-146b |
|
Causal |
Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. |
2008 |
|
|
|
|
|
|
| hsa-miR-206 |
|
Causal |
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-451 |
|
Causal |
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. |
2008 |
|
|
|
|
|
|
| hsa-miR-146a |
|
Causal |
A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
|
2008 |
|
|
|
|
|
|
| hsa-miR-20a |
|
Causal |
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
|
2008 |
|
|
|
|
|
|
| hsa-miR-128a |
|
Causal |
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
|
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Causal |
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
|
2008 |
|
|
|
|
|
|
| hsa-miR-516-3p |
|
Causal |
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
|
2008 |
|
|
|
|
|
|
| hsa-miR-7 |
|
Causal |
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
|
2008 |
|
|
|
|
|
|
| hsa-let-7f |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-127 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-181b |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-181d |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-29b |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-29c |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-30a-3p |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-31 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-320 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-355 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-365 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-497 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-98 |
|
Unspecified |
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-221 |
|
Unspecified |
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1. |
2008 |
|
|
|
|
|
|
| hsa-miR-222 |
|
Unspecified |
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1. |
2008 |
|
|
|
|
|
|
| hsa-miR-221 |
|
Causal |
MicroRNA-221/222 Negatively Regulates Estrogen Receptor{alpha} and Is Associated with Tamoxifen Resistance in Breast Cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-222 |
|
Causal |
MicroRNA-221/222 Negatively Regulates Estrogen Receptor{alpha} and Is Associated with Tamoxifen Resistance in Breast Cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Causal |
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. |
2008 |
|
|
|
|
|
|
| hsa-miR-7 |
|
Causal |
MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. |
2008 |
|
|
|
|
|
|
| hsa-miR-204 |
|
Causal |
MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-510 |
|
Causal |
MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. |
2008 |
|
|
|
|
|
|
| hsa-miR-126 |
|
Causal |
The cell growth suppressor, mir-126, targets IRS-1. |
2009 |
|
|
|
|
|
|
| hsa-miR-7 |
|
Causal |
Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. |
2009 |
|
|
|
|
|
|
| hsa-miR-328 |
|
Unspecified |
MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-205 |
|
Causal |
microRNA-205 regulates HER3 in human breast cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-125a |
|
Unspecified |
Germline mutation of microRNA-125a is associated with breast cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. |
2009 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion. |
2009 |
|
|
|
|
|
|
| hsa-miR-200c |
|
Causal |
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. |
2009 |
|
|
|
|
|
|
| hsa-miR-31 |
|
Causal |
A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. |
2009 |
|
|
|
|
|
|
| hsa-miR-9-3 |
|
Causal |
Xenoestrogen-Induced Epigenetic Repression of microRNA-9-3 in Breast Epithelial Cells. |
2009 |
|
|
|
|
|
|
| hsa-miR-125b |
|
Unspecified |
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis |
2009 |
|
|
|
|
|
|